# Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

> **NCT01167166** · PHASE1,PHASE2 · COMPLETED · sponsor: **Traws Pharma, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Acute Myelocytic Leukemia
- Acute Lymphocytic Leukemia
- Myeloproliferative Disease
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** rigosertib

## Key facts

- **NCT ID:** NCT01167166
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-12
- **Final completion:** 2014-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01167166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01167166, "Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01167166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*